Bionano Genomics enters new $75M ATM sales agreement with H.C. Wainwright, replacing Cowen facility

Bionano Genomics, Inc.

Terminated prior Cowen sales agreement effective Feb 14, 2025; suspended offering Feb 4.
New ATM with H.C. Wainwright allows sale of up to $75M of common stock at market prices.
Wainwright receives 3.0% commission on gross proceeds from each sale.
Shares sold on Nasdaq through at-the-market offerings; company may suspend at any time.
Registration statement on Form S-3 effective May 10, 2023, covering the new facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.